Let's make a deal! Staring David S. Tierney!
David S. Tierney, M.D. is President and CEO of Icon Bioscience where he led a team that in 2018 received U.S. FDA approval of its New Drug Application for DEXYCU™. Previously, Dr. Tierney was Co-Founder and President of Oceana Therapeutics, sold to Salix Pharmaceuticals in December 2011. Dr. Tierney served as President and CEO of Valera Pharmaceuticals, between August 2000 and April 2007, when Valera completed a merger with Endo Pharmaceuticals. Prior to this Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities. Roberts was acquired by Shire. Before Roberts, Dr. Tierney was employed by Élan Corporation in a variety of management positions.
BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer
"BioPharmX is on the threshold of an important and exciting growth phase as is evident from the company's robust product pipeline and its lead product candidate being phase 3-ready for acne."
David S. Tierney
